Close Menu

NEW YORK – With the launch last week of its PrecivityAD test, C2N Diagnostics has become the first company to bring a blood-based test for Alzheimer's to market.

The company anticipates that the test, which uses mass spectrometry to measures levels of amyloid beta (Aβ) and apolipoprotein E in patient blood, will see uptake among physicians looking for additional information to evaluate patients they suspect of having Alzheimer's, and drug companies in need of a quick and relatively inexpensive test for selecting subjects for clinical trials.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.